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OBJECTIVE—To investigate the associations of plasma levels of advanced glycation end
products (AGEs) with incident cardiovascular disease (CVD) and all-cause mortality in type 1
diabetes and the extent to which any such associations could be explained by endothelial and
renal dysfunction, low-grade inﬂammation, and arterial stiffness.
RESEARCH DESIGN AND METHODS—We prospectively followed 169 individuals
with diabetic nephropathy and 170 individuals with persistent normoalbuminuria who were
free of CVD at study entry and in whom levels of N
´-(carboxymethyl)lysine, N
´-(carboxyethyl)
lysine, pentosidine and other biomarkers were measured at baseline. The median follow-up
duration was 12.3 (interquartile range 7.6–12.5) years.
RESULTS—D u r i n gt h ec o u r s eo ff o l l o w - u p ,8 2i n d ividuals (24.2%) died; 85 (25.1%)
suffered a fatal (n = 48) and/or nonfatal (n = 53) CVD event. The incidence of fatal and nonfatal
CVD and of all-cause mortality increased with higher baseline levels of AGEs independently of
traditional CVD risk factors: hazard ratio (HR) = 1.30 (95% CI = 1.03–1.66) and HR = 1.27
(1.00–1.62), respectively. These associations were not attenuated after further adjustments for
markers of renal or endothelial dysfunction, low-grade inﬂammation, or arterial stiffness.
CONCLUSIONS—Higher levels of AGEs are associated with incident fatal and nonfatal CVD
as well as all-cause mortality in individuals with type 1 diabetes, independently of other risk
factors and of several potential AGEs-related pathophysiological mechanisms. Thus, AGEs may
explain,inpart,theincreasedcardiovasculardiseaseandmortalityattributabletotype1diabetes
and constitute a speciﬁc target for treatment in these patients.
Diabetes Care 34:442–447, 2011
D
iabetes is characterized by hyper-
glycemia and associated with in-
creased cardiovascular disease
(CVD) risk (1). Advanced glycation end
products (AGEs) may link hyperglycemia
to the development of vascular complica-
t i o n si nd i a b e t e s( 2 ) .A G E sa f f e c tc e l l si n
three general ways: 1) cellular functions
can be altered when intracellular proteins
are modiﬁed by AGEs; 2)m o d i ﬁcation of
extracellularmatrixproteinsresultsinab-
normalinteractionsbetweentheseproteins;
and 3) circulating AGEs can bind to AGE
receptors, which could induce receptor-
mediated production of reactive oxygen
species and activate transcription factor nu-
clear factor-kB, thereby leading to deleteri-
ous changes in cellular processes (2).
Several studies so far have examined
the associations between various plasma
AGEs and microvascular and macrovas-
cular complications in subjects with (3–
12) or without (6–8,13–15) diabetes,
most of which were conﬁned to speciﬁc
study populations (i.e., in elderly, pa-
tients with end-stage renal failure, pa-
tients with heart failure, or women only)
(6,7,13,14) and/or had a cross-sectional
design (3,5,10–12). Among the few pro-
spective studies, most have reported pos-
itive associations between plasma AGEs
and (CVD) mortality in patients with
(8,9) or without(6,7,14,15)type 2diabe-
tes. However, so far, no prospective stud-
ies have investigated the associations
between plasma AGEs and incident car-
diovascular complications in patients
with type 1 diabetes. In addition, the
mechanisms through which AGEs could
lead to the development of CVD in these
individuals are unclear. Endothelial (2)
and renal dysfunction (16), low-grade in-
ﬂammation (2,14), and arterial stiffness
(2) could constitute such mechanisms.
In view of these considerations, we
have investigated, in a 12-year prospective
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Pathophysiology/Complications
ORIGINAL ARTICLEfollow-up study 1) whether plasma levels
of N
´-(carboxyethyl)lysine (CEL), N
´-
(carboxymethyl)lysine (CML), and pento-
sidine were associated with incident fatal
and nonfatal CVD as well as all-cause mor-
tality in individuals with type 1 diabetes
and 2) whether the extent to which any
such associations were explained (i.e., me-
diated)bymarkersofendothelialandrenal
dysfunction, low-grade inﬂammation, and
arterial stiffness.
RESEARCH DESIGN AND
METHODS
Study population and design
In1993,199patientswithtype1diabetes
and diabetic nephropathy deﬁned ac-
cording to clinical criteria (i.e., persistent
macroalbuminuria [.300 mg/24 h] in at
least two out of three previous consecu-
tive 24-h urine collections, in the pres-
ence of diabetic retinopathy, and in the
absence of other kidney or urinary tract
disease)and192withpersistentnormoal-
buminuria (i.e., urinary excretion rate
,30 mg/24 h) were recruited from the
outpatient clinic at Steno Diabetes Center
for a prospective observational follow-up
study. Details of the inclusion criteria and
selection procedures have been described
elsewhere (17). The study was approved
by the local ethics committee, in accor-
dance with the Helsinki Declaration, and
all patients gave their informed written
consent.
Baseline investigations
Biomarkers. Analyses of the biomarkers
were done on frozen (280°C) samples
and were performed at a central labora-
tory by C.G.S.
The AGEs CML, CEL, and pentosi-
dine were measured as described (18,19)
with minor modiﬁcations. In brief, to
measure CEL, CML, and pentosidine,
50 mL plasma was mixed with 100 mLw a -
ter in a 10-mL glass tube with a Teﬂon-
lined screw-cap. To prevent formation of
AGEsfromearlyglycationproductsduring
sample preparation, plasma samples were
reduced by 500 mL sodium borohydride
borate buffer (200 mmol/L, pH 9.2) before
precipitation. This mixture was allowed to
standfor2hatroomtemperature.Proteins
were then precipitated byaddition of2 mL
20% trichloroacetic acid and centrifuged
for 10 min (4°C) at 4,500 3 g. The super-
natant was carefully removed by aspira-
tion with a Pasteur pipette. The protein
pellet was washed once by adding 2 mL
5% trichloroacetic acid followed by
centrifugation and removal of the super-
natant. The samples were hydrolyzed by
adding 1,000 ml 6 N HCl and incubated
for 18 h at 110°C.
Afterhydrolysis,100mLofthesesam-
ples were evaporated to dryness at 80°C
under a stream of nitrogen gas and recon-
stituted in 200 mL 0.5 mmol/L trideca-
ﬂuoroheptanoic acid for the CEL and
CML measurements. Five microliters of
this solution were injected on the ultra-
performance liquid chromatography tan-
dem mass spectrometry. Liquid chroma-
tography was performed at 30°C using an
Acquity UPLC BEH C18, 1.7 mm, 2.1 3
100 mm column (Waters, Milford, MA),
and the Micromass Quattro Premier XE
Tandem Mass Spectrometer (Waters)
was used in the multiple reaction monitor-
ing mode in the electrospray ionization–
positive mode. The intra- and interassay
coefﬁcients of variation (CVs) were 7.3%
and 2.0% for CEL and 3.5% and 3.6% for
CML, respectively.
For the pentosidine measurement,
900 mL of the hydrolyzed samples were
evaporated to dryness at 80°C under a
stream of nitrogen gas and reconstituted
in 200 mL 25 mmol/L citric acid. This so-
lutionwascentrifuged for10min(4°C)at
4,500 3 g, and 10 mL of this solution
were injected on the high-performance
liquid chromatography system. Detec-
tion was carried out using a Jasco type
821-FPspectroﬂuorometer(JascoBenelux,
Maarssen, the Netherlands) set at an exci-
t a t i o na n de m i s s i o nw a v e l e n g t ho f3 2 5
and 385 nm, respectively. The intra-
and interassay CVs were 2.7% and 2.8%
for pentosidine, respectively.
High-sensitivity C-reactive protein
(hs-CRP) and secreted phospholipase A2
(sPLA2) were determined by enzyme-
linked immunosorbent assays (ELISA) as
described previously (20). Commercially
available ELISA kits were used for mea-
surements of plasma soluble vascular cell
adhesion molecule-1 (sVCAM-1), solu-
ble intercellular adhesion molecule-1
(sICAM-1), and interleukin-6 (IL-6)
(Quantikine High Sensitivity; R&D Sys-
tems, Oxon, U.K.). The intra- and interas-
sayCVsoftheseimmunoassayswere,8%.
Other baseline assessments. All inves-
tigations were performed in the morning
after an overnight fast. No antihyperten-
sive medication was ever prescribed in
24% of patients with nephropathy and
88% of the normoalbuminuric patients.
All of the remaining patients were asked
tostoptheirantihypertensiveanddiuretic
treatment 8 days before the examination.
Arterial blood pressure was measured
twice with an appropriate cuff size fol-
lowing at least a 10-min rest in the supine
position. Mean arterial pressure (MAP)
wascalculatedas[systolicbloodpressure+
(2*diastolicbloodpressure)]/3.Pulsepres-
sure was calculated by subtracting the di-
astolic from the systolic blood pressure
and used as a marker of arterial stiffness
(21). BMI was calculated by dividing
weight by height squared. Urinary albu-
minexcretion(UAE)wasmeasuredbyan
enzyme immunoassay from 24-h urine
collections. Serum creatinine concentra-
tion was assessed by a kinetic Jaffé
method. In all patients glomerular ﬁltra-
tion rate (eGFR) was estimated according
to the short Modiﬁcation of Diet in Renal
Disease equation (MDRD) = 186 z [serum
creatinine (mg/dL)]
21.154 z [age]
20.203 z
[0.742 if patient is female]. Patients were
interviewed using the World Health Organi-
zationcardiovascularquestionnaire.Individ-
uals were categorized into three groups
according to their smoking status as never,
former, or current smokers.
Follow-up and study end points
All patients were followed up to the last
visit at Steno Diabetes Center until Sep-
tember 1, 2006 or until death (n = 82) or
emigration (n = 3). All patients were
traced through the national register dur-
ing autumn 2006. If a patient had died
before September 1, 2006, the date of
death was recorded and information on
the primary cause of death was obtained
from the death certiﬁcate, which was re-
viewed by two independent observers.
Additional available information from
necropsy reports was also included. All
deaths were classiﬁed as cardiovascular
unless an unequivocal noncardiovascular
cause was established. In all patients alive
at the end of follow-up, nonfatal cardio-
vascular events were retrieved from their
patient ﬁles from Steno Diabetes Center
and/orotherhospitalrecords.Theprimary
study outcome was a combined end point
of fatal and nonfatal cardiovascular disease
(i.e., myocardial infarction, percutaneous
coronary intervention, coronary bypass
grafting, amputation because of ischemia,
vascular surgery for peripheral atheroscle-
rotic disease, and stroke), and the secondary
outcome was all-cause mortality.
Statistical analyses
All analyses were performed with the
Statistical Package for Social Sciences
(SPSS) version 15.0 for Windows (SPSS,
Chicago, IL).
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Nin and AssociatesVariables with a skewed distribution,
i.e., triglycerides, CRP, IL-6, sPLA2,U A E ,
and pentosidine, were loge transformed
before further analyses. Comparisons
of baseline characteristics between
groups were performed with Student
t or x
2 tests, as appropriate. To investi-
gate the association between CEL, CML,
Ln-pentosidine, and an AGEs score (cal-
culated by averaging the z-scores of CEL,
CML, and Ln-pentosidine) on the one
handandincidentCVDaswellasall-cause
mortality on the other, we used Cox pro-
portional hazards regression models.
These analyses were adjusted, ﬁrst, for
sex,age,durationofdiabetes,case-control
status, and A1C; second, for other cardio-
vascular risk factors (i.e., BMI, smoking
status, total cholesterol, and MAP); and
third, for the use of renin-angiotensin-
aldosterone system (RAAS) inhibitors
and/or other antihypertensive treatment.
This model was then further adjusted
for markers of renal dysfunction (i.e.,
eGFRMDRD and Ln-UAE), low-grade in-
ﬂammation (expressed as a total score
computed by averaging the z-scores of
Ln-IL-6, Ln-CRP, sICAM-1, and Ln-
sPLA2), endothelial dysfunction (ex-
pressed as a total score computed by
averaging the z-scores of sVCAM-1 and
sICAM-1), and arterial stiffness (i.e.,
pulse pressure); these markers were en-
tered one at a time to ascertain the extent
to which any such marker could attenu-
ate (i.e., explain) the strength of the asso-
ciation between the AGEs and study end
points, which were given as hazard ratios
(HR) with 95% CIs.
We used linear regression analyses
to investigate the cross-sectional associa-
tions between CEL, CML, Ln-pentosidine,
and AGEs score on the one hand and
markers of renal dysfunction, low-grade
inﬂammation, endothelial dysfunction,
and arterial stiffness on the other. Results
of these analyses are expressed in stan-
dardized regression coefﬁcients to allow
comparison of the strength of the associ-
ation between the AGEs and each of these
variables.
Finally, we investigated whether
the associations listed above differed
between patients with normoalbuminu-
ria and those with nephropathy by add-
ing interaction terms to our models,
the signiﬁcance of which was judged
on the basis of a P value ,0.1 for
the interaction term. We found no such
interactions, and, therefore, all results
are presented for the two groups com-
bined.
RESULTS—Of the 391 patients in-
cluded in this study, we excluded 17 (1
with nephropathy and 16 with normoal-
buminuria) in whom follow-up data were
not obtained, 4 with missing data on
baseline biomarkers levels (1 patient
with nephropathy and 3 patients with
normoalbuminuria), 7 with end-stage re-
nal failure, and 24 with prior CVD at
baseline (21 patients with nephropathy
and 3 with normoalbuminuria). Results
reported herein thus refer to 339 patients
(170 with persistent normoalbuminuria
and 169 with nephropathy at baseline).
During the course of follow-up (me-
dian 12.3 years [interquartile range 7.6–
12.5]), 82 individuals (24.2%) died; 85
(25.1%) suffered a fatal (n = 48) and/or
nonfatal (n = 53) CVD event. Individuals
with incident CVD events or who had
died at follow-up had, at baseline, higher
levelsofAGEs andamoreadverseathero-
sclerotic risk proﬁle as illustrated by the
more unfavorable levelsof traditional risk
factors, markers of endothelial dysfunc-
tion, low-grade inﬂammation, and pulse
pressure (Table 1).
After adjustments for age, sex, dura-
tion of diabetes, A1C, case-control status,
other risk factors, and the use of medica-
tion, the incidence of fatal and nonfatal
CVD increased with a HR of 1.30 (1.03–
1.66) per 1 SD increase in baseline levels
o fA G E ss c o r e( T a b l e2 ,m o d e l3 ) .T h e
HRs for incident fatal and nonfatal CVD
per 1 SD increase in baseline CEL, CML,
and Ln-pentosidine were comparable:
H R=1 . 2 4( 1 . 0 1 –1.52), HR = 1.22
(0.96–1.56), and HR = 1.29 (1.03–
1.60), respectively (Supplementary
Table 1, model 3). Similar results were
found for the associations between the
AGEs and incident all-cause mortality:
H R=1 . 2 2( 1 . 0 0 –1.49), HR = 1.17
(0.91–1.50), and HR = 1.28 (1.03–
1.59), respectively (Table 2; Supplemen-
tary Table 2 for analyses for each AGE
separately).
If we excluded from the analyses the
CVDcasestowhichanunequivocalCVD-
related cause of death could not be as-
cribed, our results did not change: HR =
1.31 (1.02–1.70) after adjustments for
age, sex, duration of diabetes, A1C,
case-control status, other risk factors,
and the use of medication.
The associations between AGEs and
CVD and all-cause mortality were
comparable between patients with nor-
moalbuminuria and nephropathy at base-
line: HR = 1.60 (95% CI 0.68–3.80) and
H R=1 . 3 5( 1 . 0 5 –1.73) for CVD and
HR = 1.32 (0.48–3.63) and 1.37 (1.06–
1.77) for all-cause mortality, respectively.
It should be noted that the wider CIs
aroundtheestimatesinthenormoalbumi-
nuria group were most likely because
of the relatively low number of events
(21 CVDs and 18 deaths in this group).
Adjustment for markers of renal dys-
function (model 4a), low-grade inﬂamma-
tion (model 4b), endothelial dysfunction
(model 4c), and arterial stiffness (model
4d) did not attenuate the associations
between the AGEs and the study end
points, despite the adverse associations
between plasma AGEs and most of these
pathophysiological mechanisms (Table
3; Supplementary Table 3 for the associ-
ations presented for each AGE sepa-
rately).
Because the two markers (Ln-UAE
and eGFR) of renal dysfunction were
interrelated (standardized b = 20.52,
95% CI 20.61 to 20.43) and because
both markers individually were inversely
associated with AGEs (Table 3), although
Ln-UAE was positively and eGFR was in-
versely associated with incident CVD, ad-
justments for renal dysfunction were
performed by adjustments for both base-
lineLn-UAEandeGFRtoensurethemost
appropriate correction for renal dysfunc-
tion (Table 3, model 4a).
Additional analyses
Patients were asked to stop their antihy-
pertensive and diuretic treatment 8 days
before the examination. However, 27%
and 4% of patients in the nephropathy
and normoalbuminuria groups, respec-
tively, had taken antihypertensive medi-
cation on the day of examination. The
associations between AGEs and study
outcomes did not appreciably differ be-
tween those who did or did not withhold
their medication at baseline examination,
nor did they change after additional ad-
justment for medication withdrawal sta-
tus (data not shown).
CONCLUSIONS—The main ﬁndings
of this study were that in patients with
type 1 diabetes higher baseline plasma
levels of AGEs are associated with inci-
dent fatal and nonfatal CVD as well as
all-cause mortality, independently of tra-
ditional cardiovascular risk factors, but
also of markers of renal and endothelial
dysfunction, low-grade inﬂammation,
and arterial stiffness. AGEs may thus
c o n s t i t u t eas p e c i ﬁc target for treatment
to prevent the excess CVD and mortality
observed in patients with type 1 diabetes.
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AGEs and complications in type 1 diabetesOur results are in agreement with
studies that have shown positive associa-
tions between plasma levels of AGEs or
Amadori products, speciﬁcally non-CML
AGE (11), pentosidine (3) and Amadori-
albumin (22), and microvascular compli-
cations, but these studies were limited by
their cross-sectional designs (3,11,22)
and/or were conﬁned to small study
populations (3,11). This is the ﬁrst pro-
spective study that has examined the as-
sociations between plasma CEL, CML,
and pentosidine and incident fatal and
nonfatal CVD as well as all-cause mortal-
ityinalargesampleofpatientswithtype1
diabetes and that has also addressed the
potentialpathophysiologicalmechanisms
that may explain the associations
observed. Our ﬁndings are also in agree-
ment with two previous studies, which
have related higher skin autoﬂuorescence
(23),asapotentialmarkerfortissueAGEs
accumulation, and AGEs levels in skin
collagen (24) with incident coronary
heart disease and microvascular compli-
cations in patients with type 1 diabetes,
respectively. Whether and to what extent
skin autoﬂuorescence is associated with
plasmaAGEslevelsstillneedstobeinves-
tigated.
We investigated three out of many
differentAGEs,allofwhichwereassociated
with incident fatal and nonfatal CVD to a
similar extent. Based on their molecular
characteristics one could hypothesize that
each AGE could exert unfavorable effects
on cellular functions through (partially)
different pathways. However, CEL (as a
putativemarkerofintracellularglycation),
CML (as a potential ligand of RAGE), and
pentosidine (as one of the cross-linking
AGEs) were highly correlated with each
other (correlation coefﬁcients all .0.7)
and, therefore, in mutually adjusted anal-
yses, none was independently associated
with study outcomes (Supplementary
Tables 1 and 2, model 5). These ﬁndings
suggest that the adverse effects of CEL,
CML, and pentosidine on cardiovascular
riskintype1diabeteslargelyoverlap.Fur-
ther studies may be needed to unravel the
speciﬁc effects, if any, of intracellular
protein glycation, formation of cross-
links in the extracellular matrix, and the
Table 1—Baseline characteristics according to the occurrence of primary and secondary end points during follow-up
Individuals
with primary
end point
N =8 5
Individuals
without primary
end point
N =2 5 4 P value
Individuals
with secondary
end point
N =8 2
Individuals
without secondary
end point
N = 257 P value
Sex, male/female (%) 61/39 60/40 0.901 68/32 58/42 0.156
Age (years) 44.7 (9.0) 40.3 (9.6) ,0.001 45.5 (9.9) 40.1 (9.2) ,0.001
Duration of diabetes (years) 30.7 (8.8) 26.8 (7.5) ,0.001 30.3 (10.0) 27.0 (7.1) 0.006
Nephropathy: yes (%) 75 41 ,0.001 78 41 ,0.001
Retinopathy: no/simplex/proliferative (%) 8/37/55 21/45/34 ,0.001 6/37/57 21/45/34 ,0.001
A1C (%) 9.5 (1.5) 8.9 (1.4) ,0.001 9.6 (1.5) 8.8 (1.4) ,0.001
BMI (kg/m
2) 23.9 (3.3) 23.9 (2.8) 0.991 23.7 (3.2) 23.9 (2.9) 0.571
Total cholesterol (mmol/L) 5.70 (1.10) 4.99 (1.12) ,0.001 5.80 (1.13) 4.97 (1.10) ,0.001
HDL cholesterol (mmol/L) 1.43 (0.42) 1.55 (0.55) 0.033 1.52 (0.48) 1.52 (0.54) 0.961
Triglycerides (mmol/L) 1.24 (0.93–1.70) 0.81 (0.63–1.19) ,0.001 1.28 (0.90–1.66) 0.81 (0.64–1.16) ,0.001
Creatinine (mmol/L) 104 (77–150) 80 (71–92) ,0.001 105 (78–147) 79 (72–92) ,0.001
eGFRMDRD (mL/min/1.73 m
2) 65.5 (29.1) 86.8 (21.1) ,0.001 65.5 (27.8) 86.6 (21.9) ,0.001
UAE rate (mg/24 h) 644 (33–1,940) 17 (7–525) ,0.001 720 (82–2,012) 16 (7–468) ,0.001
Blood pressure (mmHg)
Systolic 157 (24) 136 (20) ,0.001 159 (24) 136 (19) ,0.001
Diastolic 85 (13) 79 (12) 0.001 86 (14) 79 (11) ,0.001
MAP 109 (15) 98 (13) ,0.001 111 (15) 98 (13) ,0.001
Pulse pressure (mmHg) 73 (21) 57 (15) ,0 . 0 0 1 7 3( 2 1 ) 5 7( 1 5 ) ,0.001
RAAS inhibitors: yes (%) 51 20 ,0.001 50 20 ,0.001
Other antihypertensive medication: yes (%) 64 28 ,0.001 68 27 ,0.001
Smoking: never/former/current (%) 28/19/53 37/17/46 0.513 26/17/57 38/18/44 0.085
CEL (mmol/L) 1.02 (0.28) 0.92 (0.19) 0.004 1.03 (0.30) 0.92 (0.18) 0.003
CML (mmol/L) 3.60 (1.12) 3.54 (0.84) 0.634 3.56 (1.32) 3.55 (0.75) 0.967
Pentosidine (pmol/mg) 49.3 (35.7–71.8) 40.8 (34.0–49.0) 0.001 51.8 (34.2–73.1) 41.0 (34.2–48.9) 0.001
AGE score 0.26 (1.17) 20.09 (0.79) 0.012 0.27 (1.32) 20.08 (0.72) 0.024
C-reactive protein (mg/L) 1.59 (0.64–3.22) 0.96 (0.41–2.09) 0.008 1.42 (0.59–3.26) 1.02 (0.44–2.16) 0.021
sPLA2 (mg/mL) 4.40 (2.80–7.00) 4.00 (2.70–6.23) 0.329 4.05 (2.80–6.55) 4.00 (2.70–6.55) 0.948
IL-6 (pg/mL) 2.18 (1.52–3.45) 1.49 (0.99–2.35) ,0.001 2.42 (1.75–3.89) 1.44 (1.00–2.21) ,0.001
sICAM-1 (ng/mL) 771 (258) 726 (272) 0.182 805 (286) 715 (260) 0.008
Low-grade inﬂammation score 0.21 (0.57) 20.07 (0.68) 0.001 0.23 (0.65) 20.07 (0.65) ,0.001
sVCAM-1 (ng/mL) 1,045 (269) 984 (346) 0.141 1,100 (346) 967 (318) 0.001
Endothelial dysfunction score 0.13 (0.70) 20.04 (0.81) 0.074 0.28 (0.85) 20.09 (0.75) ,0.001
Data are means (SD), median (interquartile range), or percentages, as appropriate. Primary end point was a combined end point of fatal and nonfatal CVD, and the
secondary end point was all-cause mortality. During the course of follow-up, 82 individuals died; 85 suffered a fatal (n = 48) and/or nonfatal (n = 53) CVD event.
eGFRMDRD, estimated glomerular ﬁltration rate by abbreviated modiﬁcation of diet in renal disease equation.
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attributable to AGEs in type 1 diabetes.
Although some minor differences
were found in the adverse associations
between each of the AGEs on the one
hand and markers of renal and endothelial
dysfunction, low-grade inﬂammation, and
pulse pressure on the other, overall, none
of these pathophysiological mechanisms
investigated explained the positive asso-
ciations between the AGEs and incident
fatalandnonfatalCVDaswellasall-cause
mortality. We cannot discard the possi-
bility that the use of a selection of markers
representing renal and endothelial dys-
function, low-grade inﬂammation, and
arterial stiffness may have led to an un-
derestimation of their mediating effects in
those associations, however. Further-
more, other mechanisms (e.g., oxidative
stress) not investigated herein could also
play a role in the link between AGEs and
CVD. It is noteworthy that markers of
renal dysfunction, speciﬁcally UAE (but
not eGFR), and of arterial stiffness, i.e.,
pulse pressure, did not attenuate the
associations between AGEs and incident
fatal and nonfatal CVD as well as all-cause
mortality, but were associated with in-
cident fatal and nonfatal CVD indepen-
dently of AGEs and other risk factors
(HR = 2.19 [1.17 – 4.10] and HR = 1.53
[1.15 – 2.02], respectively). These ﬁndings
thus suggest that all three mechanisms
may need speciﬁc monitoring/treatment
to decrease excess CVD in diabetes.
There are limitations to our study.
First, samples for analyses of AGEs and
other biomarkers were taken at baseline
only, which impedes evaluation of the
impact of changes in these variables on
cardiovascular outcome. Second, poten-
tial misclassiﬁcation of nonspeciﬁcm o r -
tality as CVD-related mortality may have
introduced nondifferential biases, in
which case the estimates reported herein
may have been underestimated. How-
ever, we cannot discard the possibility
that ourresults mayhavebeen affectedby
possible differential underreporting of
nonfatal CVD. Third, we measured
plasma levels of three speciﬁc AGEs, and
it is not clear whether these are represen-
tative of the total pool of AGEs. In
addition, AGEs accumulate in tissue and
cellularconcentrationsofAGEsarehigher
than plasma AGE levels (25). Further
studies in which both plasma and tissue
levelsofAGEsaremeasuredareneededto
clarify the relation between the AGEs lev-
els in these two compartments and their
speciﬁc association to CVD. Fourth, we,
like most of other studies conducted in
humans (4–9,11–13), did not normalize
the plasma AGE levels for an amino acid
concentration, which may not enable di-
rect comparison (of absolute values) with
some other studies (3,5,10,12,14,15).
Nevertheless, we do not think normaliza-
tion for an amino acid concentration is
likely to affect the associations between
plasma AGEs and study end points in our
presentstudy,because inpreliminaryanal-
yses (in a different cohort) we observed
very strong correlations (r . 0.9) between
normalized and non-normalized values of
AGEs and comparable associations of nor-
malizedand non-normalizedplasma AGEs
levels with outcome (data not shown).
In conclusion, higher plasma levels
of AGEs at baseline are associated with
incident fatal and nonfatal CVD as well as
Table 2—Associations between baseline plasma AGEs and incident primary and
secondary end points (n = 339)
Model
Primary end point (85 events) Secondary end point (82 events)
HR 95% CI P value HR 95% CI P value
1 1.33 1.05–1.69 0.018 1.34 1.06–1.69 0.013
2 1.36 1.08–1.73 0.011 1.34 1.06–1.69 0.013
3a 1.35 1.07–1.71 0.013 1.36 1.07–1.72 0.011
3b 1.31 1.03–1.66 0.026 1.25 0.99–1.59 0.060
3 1.30 1.03–1.66 0.029 1.27 1.00–1.62 0.047
4a 1.31 0.99–1.73 0.057 1.27 0.95–1.68 0.103
4b 1.26 1.00–1.61 0.055 1.24 0.98–1.58 0.076
4c 1.31 1.00–1.62 0.028 1.26 1.00–1.59 0.051
4d 1.30 1.02–1.66 0.036 1.28 1.01–1.64 0.046
Primary end pointwas acombined end pointof fataland nonfatal CVD, andthe secondary end pointwasall-
cause mortality. During the course of follow-up, 82 individuals died; 85 suffered a fatal (n = 48) and/or
nonfatal (n = 53) CVD event. Model 1 is adjusted for age, sex, A1C, case-control status, and duration of
diabetes; model 2: model 1 + BMI, MAP, smoking status, and total cholesterol; model 3a: model 2 + RAAS
inhibitors;model3b:model2+otherantihypertensiveagents;model3:model2+RAASinhibitorsandother
antihypertensive agents; model 4a: model 3 + eGFR by abbreviated modiﬁcation of diet in renal disease
equation and Ln-UAE rate; model 4b: model 3 + low-grade inﬂammation score; model 4c: model 3 + en-
dothelial dysfunction score; model 4d: model 3 + pulse pressure.
Table 3—Associations between plasma AGEs and potential mechanisms linking AGEs to
incident CVD and all-cause mortality (n = 339)
Dependent variable
All
b 95% CI P value
Baseline eGFRMDRD
Model 1 20.32 20.42 to 0.23 ,0.001
Model 2 20.29 20.39 to 20.20 ,0.001
Ln-UAE rate
Model 1 20.07 20.12 to 20.02 0.008
Model 2 20.04 20.09 to 0.00 0.071
Inﬂammatory score
Model 1 0.06 20.02 to 0.14 0.123
Model 2 0.09 0.01–0.17 0.036
Endothelial dysfunction score
Model 1 0.13 0.03–0.22 0.008
Model 2 0.13 0.03–23 0.009
Pulse pressure
Model 1 0.03 20.08 to 0.14 0.591
Model 2 0.03 20.07 to 0.12 0.615
b, standardized regression coefﬁcient indicates change in dependent variable (in SD) per 1 SD increase
in baseline AGEs score. Model 1, adjusted for age, sex, duration of diabetes, case-control status, and A1C;
model 2, model 1 + BMI, smoking status, MAP, total cholesterol, use of RAAS inhibitors, other antihyper-
tensive treatment, and continuation of medication at baseline examination.
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AGEs and complications in type 1 diabetesall-cause mortality in type 1 diabetes in-
dependentofotherriskfactorsandmaythus
constituteapathway,whichexplains,atleast
in part, the increased CVD risk attributable
to type 1 diabetes in these patients.
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